Sciensus integrates real-world treatment delivery, patient engagement and evidence generation to support access decisions, reimbursement and long-term commercial success.

Accelerate access

Proactive, fit-for-purpose evidence strategies including early access and post-approval evidence generation

Leverage patient engagement

Evidence is generated within routine European care pathways, compliantly embedded into distribution and patient support programmes

Activate evidence

Influence decisions with real-world utilisation, outcomes and patient-reported data

Alignment with regulatory, HTA and payer expectations helps reduce uncertainty and de-risk access decisions.

Our expertise, proven at scale

- **30 years** of experience
- **$2.7B** annual drugs supplied
- **4,000** established relationships with pharmacies, hospitals, wholesalers, and HCPs
- **250,000** units of orphan medicines supplied
- **>99%** on-time delivery
- **1,600** colleagues working accross Europe

PAR6770426 Implementation Date: 12/5/2026

ISPOR 2026 poster submissions: Real-world evidence insights

Poster 1

An effective methodological framework for executing multinational, patient-centred cross-sectional surveys in rare diseases

This poster outlines a scalable framework for delivering multinational, patient-centred surveys across Europe, addressing challenges around recruitment, data quality, governance and generalisability. Using a five-country study, it shows how integrated epidemiology, advocacy-led recruitment and rigorous validation can generate robust real-world evidence to inform payer discussions, regulatory strategy and commercial decision-making.

Poster 2

Surveying treatment access and support for rare diseases in Euope

This research examines real-world treatment access, medication delivery and support experiences across five European countries. Drawing on survey data, the poster highlights access burden, cross-country variation and the impact of services such as home delivery, to pinpoint where access is breaking down and to provide an opportunity to design servies that truly reduce burden and improve real-world outcomes for people living with rare diseases.

Poster 3

Pilot evaluation of AI-enabled ambient speech capture in home-based care: reducing administrative burden and enhancing real-world evidence generation for complex therapies

This poster presents an AI-enabled ambient documentation pilot (CareTranscribe) to evaluate reducing administrative burden, improving data capture and enhancing in-home clinical interactions. In addition, it will assess the ability to collect contextual insights from home-based care such as adherence barriers, education needs and practical treatment challenges, which might support enriched RWE generation outside controlled environments.

Planning to launch a therapy in Europe?

Get in touch

Evidence.Generation@sciensus.com
www.sciensus.com

Sciensus

PAR6770426 Implementation Date: 12/5/2026